

ATTORNEY DOCKET NO. 01231.0023U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
Jacobs et al.)	Art Unit: 1635
Application No. 10/563,728)	Examiner: Whiteman, B. A
Filing Date: July 21, 2006)	Confirmation No. 1957
For: MUTANTS OF VACCINIA VIRUS AS ONCOLYTIC AGENTS)))	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C. Customer Number 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. §1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

In accordance with the provisions of M.P.E.P. § 2001.06(b) and 37 C.F.R. § 1.98(b)(3),

Applicants would like to bring to the attention of the Examiner the existence of the co-pending 10/09/2007 HLE333 00000021 10563728

01 FC:1806

180.00 OP

696213

patent application(s) identified below, which were filed in the United States Patent and Trademark Office:

.

	Application No.	Date Filed	<u>Inventors</u>	Attorney Docket No.
1.	11/022,477	12/22/2004	Jacobs et al.	01231.0021U2

The pending application(s) identified is stored in the Image File Wrapper (IFW) system of the USPTO. Accordingly, copies of the cited specification(s), including the claims and drawings thereof, are not enclosed in accordance with the waiver to 37 CFR 1.98(a)(2)(iii) dated September 21, 2004.

Also enclosed are copies of documents cited by or submitted to the U.S. Patent and Trademark Office, PCT, and foreign patent offices in numerous other patent application(s). See Exhibit A attached hereto and its attachments.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(c), in that neither a final Office Action nor a Notice of Allowance has been mailed to Applicants. Accordingly, Applicants enclose the fee required under 37 C.F.R. § 1.97(c)(2).

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

A Credit Card Payment Form PTO-2038 authorizing payment in the amount of \$180.00, representing the fee under 37 C.F.R. § 1.17(p), is enclosed. This amount is believed to be

ATTORNEY DOCKET NO. 01231.0023U2 Application No. 10/563,728

correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

P. Brian Giles, Ph.D. Registration No. 57,896

NEEDLE & ROSENBERG, P.C. Customer Number 23859 (678) 420-9300 (678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-145, on the date indicated below.

P. Brian Giles, Ph.D.

Data